| Recruiting | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. NCT07165132 | RayzeBio, Inc. | Phase 1 |
| Recruiting | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen NCT07087054 | Crinetics Pharmaceuticals Inc. | Phase 3 |
| Recruiting | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Asse NCT06790706 | Hospices Civils de Lyon | Phase 2 |
| Recruiting | ALG-LungCancerRegistry (SAFRO2202) NCT07161882 | Société Algérienne de Formation et de Recherche en Oncologie | — |
| Withdrawn | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs NCT04915144 | British Columbia Cancer Agency | Phase 2 |
| Completed | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome NCT05361668 | Crinetics Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Fo NCT05477576 | RayzeBio, Inc. | Phase 3 |
| Recruiting | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tum NCT05263050 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes NCT04907643 | Cedars-Sinai Medical Center | N/A |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Unknown | Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy NCT04039516 | King's College Hospital NHS Trust | Phase 2 |
| Completed | Cabozantinib and Nivolumab for Carcinoid Tumors NCT04197310 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging NCT04017104 | British Columbia Cancer Agency | — |
| Terminated | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors NCT03420521 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Personalized PRRT of Neuroendocrine Tumors NCT02754297 | CHU de Quebec-Universite Laval | Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors NCT04993261 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors NCT02399215 | Roswell Park Cancer Institute | Phase 2 |
| Unknown | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors NCT02038738 | Ochsner Health System | Phase 1 / Phase 2 |
| Completed | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors NCT01782443 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT01466036 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study of Axitinib in Advanced Carcinoid Tumors NCT01435122 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. NCT01398306 | University Medical Center Groningen | — |
| Unknown | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tum NCT01175096 | Guangdong Provincial People's Hospital | Phase 1 / Phase 2 |
| Completed | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors NCT01024387 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00942682 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00804336 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma NCT00780663 | Cylene Pharmaceuticals | Phase 2 |
| Recruiting | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland NCT01039922 | Insel Gruppe AG, University Hospital Bern | — |
| Withdrawn | Clinical and Pathologic Studies in Neuroendocrine Tumors NCT00657332 | Stanford University | — |
| Completed | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor NCT00412061 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcino NCT00446082 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tu NCT00328497 | CASI Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000 NCT07317713 | Suez Canal University | — |
| Completed | The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: NCT07291752 | Suez Canal University | — |
| Completed | Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-b NCT07317726 | Suez Canal University | — |
| Completed | Endoscopic Treatment of Bronchial Carcinoid Tumors NCT03723499 | Centre Hospitalier Universitaire de Saint Etienne | — |
| No Longer Available | 18F-FDOPA PET in Neuroendocrine Tumours NCT02431715 | British Columbia Cancer Agency | — |